FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.
Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch The company has made a name for itself with a drug that treats a progressive kidney condition.
Travere Therapeutics Inc (NASDAQ:TVTX) Surpasses Q2 2025 Expectations with Strong Revenue Growth and Narrower Loss Travere Therapeutics (TVTX) reported strong Q2 2025 results, beating revenue and earnings estimates, driven by FILSPARI sales and milestone payments. Shares rose 2.3% post-earnings.
IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why Analysts are still bullish on the company's chances of being the first to win approval for an FSGS drug.
Top movers in Friday's pre-market session As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Thursday's after hours session: top gainers and losers After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage.
